Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Novel Therapy for Aggressive Cutaneous T-Cell Lymphoma Leading to Complete Clinical Remission before Allogenic Stem Cell Transplantation

Nicolas Gallastegui Crestani, MD, Mohammed E. Ibrahim, CRPH, BCOP, BCPS, BCACP, Ayman M. Mohamed, PharmD, Paolo Romanelli, MD, Amer Beitinjaneh, MD MPH, MSc, Jonathan H. Schatz, MD

Blood (2018) 132 (Supplement 1): 5354.

https://doi.org/10.1182/blood-2018-99-117079

Published: 2018

Journal Articles

Profound Hypereosinophilia Secondary to Sezary Syndrome

Ardy Davarifar, MD, Ricklie Julian, MD, Pareek Vipul, MD, Emrullah Yilmaz, MD, Amit Verma, MD

Blood (2015) 126 (23): 5053.

https://doi.org/10.1182/blood.V126.23.5053.5053

Published: 2015

Journal Articles

Sézary Syndrome: Clinicopathological and Immunophenotypical Characteristics and Outcomes

Christa Roe, RN, BS, OCN, Jennifer Rock-Klotz, BA, Elyce Turba, RN, MSN, OCN, Christopher Rodriguez Salamanca, PA, Janice Bennett, MS, ARNP-C, Farrah Farquharson, PA, Sem Bastien, MS, ARNP-C, Barbara Williams, RN, BS, OCN, Rebecca Levy, MS, ARNP-C, Yibo Li, BS, Michael Montejo, MD, Ernesto Ayala, MD, Pedro Horna, MD, Lewis F Glass, MD, Rami S. Komrokji, MD, Lubomir Sokol, MD PhD

Blood (2015) 126 (23): 1546.

https://doi.org/10.1182/blood.V126.23.1546.1546

Published: 2015

Journal Articles

The Role Of BIN1 Tumor Suppressor Isoforms In Regulation Of Proliferation, Apoptosis and Tumor Formation Of Human Cutanous T-Cell Lymphoma Cells In Vitro and In Vivo

Sharmin Esmailzadeh, Youwen Zhou, Xiaoyan Jiang, MD, PhD

Blood (2013) 122 (21): 2517.

https://doi.org/10.1182/blood.V122.21.2517.2517

Published: 2013

Journal Articles

Pyknotic Lymphocytes In Infectious Mononucleosis

William A. Dittman, Sr., MD

Blood (2013) 122 (21): 4732.

https://doi.org/10.1182/blood.V122.21.4732.4732

Published: 2013

Journal Articles

Novel Imaging Modalities in Innovative Xenograft Mouse Models of T-Cell Lymphoma Confirm Marked Synergy of Romidepsin and Pralatrexate.

Salvia Jain, MD, Xavier Jirau-Serrano, BS, Carmine F Palermo, BS, Luigi Scotto, PhD, Kenneth P Olive, PhD, Govind Bhagat, MD, Serge Cremers, PhD, Jennifer E Amengual, MD, Owen A. O'Connor, MD, PhD

Blood (2012) 120 (21): 2758.

https://doi.org/10.1182/blood.V120.21.2758.2758

Published: 2012

Journal Articles

Sezary Syndrome: Clinicopathological and Immunophenotypical Characteristics and Their Impact On Survival

Darcie Deaver, MS, ARNP, Pedro Horna, MD, Lubomir Sokol, MD, Ph.D

Blood (2012) 120 (21): 5085.

https://doi.org/10.1182/blood.V120.21.5085.5085

Published: 2012

Journal Articles

Alemtuzumab Treatment Can Affect CD52 Positive As Well As CD52 Negative GPI-Deficient, Sezary Cells Allowing Long-Term Disease Control

C.J.M. Halkes, MD, PhD, I Jedema, PhD, H.M. van Egmond, L van der Fits, PhD, J.H.F. Falkenburg, MD, PhD, MH Vermeer, MD, PhD

Blood (2011) 118 (21): 2491.

https://doi.org/10.1182/blood.V118.21.2491.2491

Published: 2011

Journal Articles

Validation of a Novel Bioluminescent Mouse Model of Sezary Syndrome for Preclinical Drug Screening

Salvia Jain, MD, Luigi Scotto, Ph.D., Enrica Marchi, MD, Ph.D., Matko Kalac, MD, Ph.D., Jennifer Amengual, M.D., Jairo Baquero Buitrago, Owen A. O'Connor, MD, PhD

Blood (2011) 118 (21): 2725.

https://doi.org/10.1182/blood.V118.21.2725.2725

Published: 2011

Journal Articles

Characterization of the Role of the Tumor Suppressor BIN1 as a Potential Mediator of the AHI-1 Oncogene in Human Cutaneous T-Cell Lymphomas

Sharmin Esmailzadeh, Helena Wang, Xiaoyan Jiang, MD, PhD

Blood (2011) 118 (21): 5229.

https://doi.org/10.1182/blood.V118.21.5229.5229

Published: 2011

Journal Articles

Graft-Versus-Lymphoma Effect After Non-Myeloablative Allogeneic Transplant Induces Molecular Remission Assessed by High-Throughput Sequencing of T Cell Receptor in Patients with Advanced Stage Mycosis Fungoides and Sezary Syndrome

Wen-Kai Weng, MD, PhD, Randy Armstrong, Sally Arai, MD, Katherine Sutherland, Richard T. Hoppe, MD, Youn H. Kim, MD

Blood (2011) 118 (21): 3114.

https://doi.org/10.1182/blood.V118.21.3114.3114

Published: 2011

Journal Articles

Alemtuzumab in Combination with Interferon-α or Gemcitabine in Aggressive and Advanced Cutaneous T-Cell Lymphomas: Report of Preliminary Results

Serena Rupoli, Gaia Goteri, Paola Picardi, Stefano Pulini, Antonello Costagliola, Lucia Canafoglia, Simonetta Mulattieri, Andrea Stronati, Anna Rita Scortechini, Marco Ottaviani, Massimiliano Nicolini, Stefano Serresi, Andreina Cellini, Anna Maria Offidani, Pietro Leoni

Blood (2008) 112 (11): 5000.

https://doi.org/10.1182/blood.V112.11.5000.5000

Published: 2008

Journal Articles

Sezary Syndrome and Combination Immunomodulatory Therapy: Improving Clinical Outcomes

Eugenia Piliotis, MD, Panayiota Govas, Kevin R Imrie, MD, Matthew C Cheung, MD, Neil Shear, Scott Walsh, MD, FRCPC, Cathy Fairlie, RN, David Barth, MD, FRCPC

Blood (2008) 112 (11): 4957.

https://doi.org/10.1182/blood.V112.11.4957.4957

Published: 2008

Journal Articles

Microarray Identification of Differentially Expressed Genes in AHI-1- Mediated Leukemic Transformation of Human Cutaneous T-Cell Lymphoma Cells.

Erin Kennah, Ashley Ringrose, Hong Qian, Xiaoyan Jiang, MD, Ph.D

Blood (2007) 110 (11): 2651.

https://doi.org/10.1182/blood.V110.11.2651.2651

Published: 2007

Journal Articles

Response to Oral Forodesine in Refractory Cutaneous T-Cell Lymphoma: Interim Results of a Phase I/II Study.

Madeleine Duvic, MD, Andres Forero-Torres, MD, Francine Foss, MD, Elise Olsen, MD, Youn Kim, MD

Blood (2007) 110 (11): 122.

https://doi.org/10.1182/blood.V110.11.122.122

Published: 2007

Journal Articles

Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status.

Francine Foss, MD, Madeleine Duvic, MD, Larisa Geskin, MD, Joseph Anderson, MD, Pierluigi Porcu, MD, Raymond J. Hohl, MD,PhD, Maureen Cooper, MD, Jasmine M. Zain, MD, John Zic, MD, Patrica Hibberd, MD,PhD, Mark Acosta, PharmD

Blood (2006) 108 (11): 2712.

https://doi.org/10.1182/blood.V108.11.2712.2712

Published: 2006

Journal Articles

Stable Suppression of a Novel Oncogene, AHI-1, in Human Cutaneous T-Cell Leukemia Cells Normalizes Its Transforming Activity In Vitro and In Vivo and Aberrant Expression of AHI-1 Is Also Present in Leukemic Sezary Cells from Patients with Sezary Syndrome.

Ashley Ringrose, Youwen Zhou, MD, Emily Pang, Ann E.-J. Lin, Xiao-Jiang Li, PhD, Irene Li, Andrew Weng, MD, PhD, Xiaoyan Jiang, MD, PhD

Blood (2005) 106 (11): 2605.

https://doi.org/10.1182/blood.V106.11.2605.2605

Published: 2005

Journal Articles

SDF-1-CXCR4 Signaling and Downregulation of CD26/Dipeptidyl-Peptidase IV Are Involved in Skin-Homing of Sezary Cells.

Giandomenico Russo, MD, Enrico Scala, MD, Antonella Bresin, PhD, Elisabetta Caprini, PhD, Maria Cristina Picchio, PhD, Daniele Remotti, MD, Gianluca Ragone, PhD, Francesca Nasorri, PhD, Marina Frontani, PhD, Cristina Cristofoletti, PhD, Diego Arcelli, PhD, Giuseppe A. Lombardo, MD, Giannandrea Baliva, MD, Monica Napolitano, MD, Maria Grazia Narducci, PhD

Blood (2005) 106 (11): 4489.

https://doi.org/10.1182/blood.V106.11.4489.4489

Published: 2005

Journal Articles

Mycosis Fungoides, Sezary Syndrome or T-Cell Prolymphocytic Leukemia?.

Pulini Stefano, MD, Rupoli Serena, MD, Scortechini Anna Rita, MD, Tassetti Angela, MD, Goteri Gaia, MD, Bartocci Chiara, MD, Discepoli Giancarlo, MD, Mulattieri Simonetta, MD, Brunori Marino, MD, Leoni Pietro, MD

Blood (2005) 106 (11): 4673.

https://doi.org/10.1182/blood.V106.11.4673.4673

Published: 2005

Journal Articles

Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Patients with Refractory Cutaneous T-Cell Lymphoma.

Madeleine Duvic, MD, Francine M. Foss, MD, Elise A. Olsen, MD, Andres Forero-Torres, MD, J. Claude Bennett, MD, Shanta Bantia, PhD, J. Michael Kilpatrick, PhD

Blood (2004) 104 (11): 2491.

https://doi.org/10.1182/blood.V104.11.2491.2491

Published: 2004

NARROW

Novel Therapy for Aggressive Cutaneous T-Cell Lymphoma Leading to Complete Clinical Remission before Allogenic Stem Cell Transplantation

Profound Hypereosinophilia Secondary to Sezary Syndrome

Sézary Syndrome: Clinicopathological and Immunophenotypical Characteristics and Outcomes

The Role Of BIN1 Tumor Suppressor Isoforms In Regulation Of Proliferation, Apoptosis and Tumor Formation Of Human Cutanous T-Cell Lymphoma Cells In Vitro and In Vivo

Pyknotic Lymphocytes In Infectious Mononucleosis

Novel Imaging Modalities in Innovative Xenograft Mouse Models of T-Cell Lymphoma Confirm Marked Synergy of Romidepsin and Pralatrexate.

Sezary Syndrome: Clinicopathological and Immunophenotypical Characteristics and Their Impact On Survival

Alemtuzumab Treatment Can Affect CD52 Positive As Well As CD52 Negative GPI-Deficient, Sezary Cells Allowing Long-Term Disease Control

Validation of a Novel Bioluminescent Mouse Model of Sezary Syndrome for Preclinical Drug Screening

Characterization of the Role of the Tumor Suppressor BIN1 as a Potential Mediator of the AHI-1 Oncogene in Human Cutaneous T-Cell Lymphomas

Graft-Versus-Lymphoma Effect After Non-Myeloablative Allogeneic Transplant Induces Molecular Remission Assessed by High-Throughput Sequencing of T Cell Receptor in Patients with Advanced Stage Mycosis Fungoides and Sezary Syndrome

Alemtuzumab in Combination with Interferon-α or Gemcitabine in Aggressive and Advanced Cutaneous T-Cell Lymphomas: Report of Preliminary Results

Sezary Syndrome and Combination Immunomodulatory Therapy: Improving Clinical Outcomes

Microarray Identification of Differentially Expressed Genes in AHI-1- Mediated Leukemic Transformation of Human Cutaneous T-Cell Lymphoma Cells.

Response to Oral Forodesine in Refractory Cutaneous T-Cell Lymphoma: Interim Results of a Phase I/II Study.

Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status.

Stable Suppression of a Novel Oncogene, AHI-1, in Human Cutaneous T-Cell Leukemia Cells Normalizes Its Transforming Activity In Vitro and In Vivo and Aberrant Expression of AHI-1 Is Also Present in Leukemic Sezary Cells from Patients with Sezary Syndrome.

SDF-1-CXCR4 Signaling and Downregulation of CD26/Dipeptidyl-Peptidase IV Are Involved in Skin-Homing of Sezary Cells.

Mycosis Fungoides, Sezary Syndrome or T-Cell Prolymphocytic Leukemia?.

Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Patients with Refractory Cutaneous T-Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only